Previous 10 | Next 10 |
The U.S. Food and Drug Administration (FDA) extended the review period of Reata Pharmaceuticals' ( NASDAQ: RETA ) application by three months drug which seeking the approval of omaveloxolone to treat Friedreich's Ataxia. The FDA is now expected to make a decisi...
Reata Submitted New Data and Analyses to Address FDA Questions During Mid-Cycle Meeting FDA Extended PDUFA Date to Provide Time for Full Review of New Submissions PDUFA Date Extended to February 28, 2023 Reata Pharmaceuticals, Inc. (Nasdaq: RE...
Recording a ~33% decline , the biggest intraday selloff since early December, the shares of Reata Pharmaceuticals ( NASDAQ: RETA ) approached a three-month low on Monday, even as Goldman Sachs issued positive views on the clinical-stage company after a potential regulatory s...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Reata Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation
Reata Pharmaceuticals, Inc. (RETA) Q2 2022 Earnings Conference Call August 8, 2022 8:30 A.M. ET Company Participants Warren Huff - Chief Executive Officer Colin Meyer - Chief Innovation Officer Dawn Bir - Chief Commercial Officer Manmeet Soni - President ...
Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...
Reata Pharma ( NASDAQ: RETA ) is trading 22% lower premarket after the company reported lower-than-expected Q2 revenue. Quarterly revenue fell ~66% to $0.76M, and missed estimates by $0.7M, hurt by lower collaboration revenue. The company posted a...
NuZee ( NUZE ) -24% on pricing $3.4M stock offering . Reata Pharmaceuticals ( RETA ) -20% on Q2 earnings release . Palantir Technologies ( PLTR ) -14% on Q2 earnings release . Digital World Acquisition ( DWACW ) -10% . Cognit...
Reata Pharmaceuticals press release ( NASDAQ: RETA ): Q2 Non-GAAP EPS of -$1.36 beats by $0.61 . Revenue of $0.76M (-65.8% Y/Y) misses by $0.7M . On June 30, 2022, we had cash and cash equivalents and marketable securities of $481.5 million, as compared to $590...
Received Priority Review and Acceptance for Filing of the NDA for Omaveloxolone for Treatment of Patients with Friedreich’s Ataxia Provides Update from FDA Mid-Cycle Communication Meeting on Omaveloxolone for Patients with Friedreich’s Ataxia An...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...